June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Antiviral activity of a 45 nucleotide DNA aptamer during HSV-1 infection of the cornea.
Author Affiliations & Notes
  • Tejabhiram Yadavalli
    Ophthalmology and Visual Sciences, University of Illionois at Chicago, Chicago, Illinois, United States
  • Neel Thakkar
    Ophthalmology and Visual Sciences, University of Illionois at Chicago, Chicago, Illinois, United States
  • Dinesh Jaishankar
    Ophthalmology and Visual Sciences, University of Illionois at Chicago, Chicago, Illinois, United States
    Bioengineering, University of Illionois at Chicago, Chicago, Illinois, United States
  • Alex Agelidis
    Ophthalmology and Visual Sciences, University of Illionois at Chicago, Chicago, Illinois, United States
  • Deepak Shukla
    Ophthalmology and Visual Sciences, University of Illionois at Chicago, Chicago, Illinois, United States
    Microbiology and Immunology, University of Illionois at Chicago, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Tejabhiram Yadavalli, None; Neel Thakkar, None; Dinesh Jaishankar, None; Alex Agelidis, None; Deepak Shukla, None
  • Footnotes
    Support  NIH Grant EY024710-02
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3599. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tejabhiram Yadavalli, Neel Thakkar, Dinesh Jaishankar, Alex Agelidis, Deepak Shukla; Antiviral activity of a 45 nucleotide DNA aptamer during HSV-1 infection of the cornea.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3599.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Herpes simplex virus type 1 (HSV-1) is the leading cause of infectious blindness in the United States. In this study, we use corneal model of HSV infection to report the high antiviral activity of a 45 nucleotide DNA aptamer directed against HSV-1 gD protein.

Methods : SYBR Green based ELISA was conducted to evaluate the specific binding affinity of the DNA aptamer by incubating 50 µL of multiple concentrations of soluble HSV-1 gD, gB proteins. MTT based cytotoxicity assay for 2 different aptamer concentrations were conducted along with a random DNA sequence and mock PBS. Viral entry and infectious spread were evaluated using β-galactosidase assay, immunoblotting and immunofluorescence assays. Freshly cut pig corneas were infected with HSV-1 GFP virus and its spread was monitored over a period of 10 days in the presence and absence of the aptamer. BALB/C mice (male and female, 3 weeks old) were anesthetized using ketamine (100 mg/kg) and xylazine (5 mg/kg) prior to scarring the right eye with a 30-G sterile needle in a 3 × 3 grid pattern. The scarred eyes were infected with GFP virus and the progress was monitored for a period of 10 days before sacrificing the mice and harvesting the tissue for analyzing the extent of virus infection and the role of cytokines through RT-PCR assay.

Results : Our DNA aptamer showed specific binding affinity towards HSV-1 gD (Kd = 50 nM) and was able to restrict viral entry by 70% at a 2 µM concentration. Immunofluorescence and immunoblotting studies showed 40-50% inhibition of viral entry and viral replication in-vitro respectively. Ex-vivo studies on pig corneal models showed therapeutic efficacy of the aptamer in reducing productive infection over a period of 168 hours. In-vivo experiments on mice models exhibited significant decrease in ocular infection through prophylactic, therapeutic and neutralization treatment of corneal tissue with the DNA aptamer.

Conclusions :
This is the first study to show a comprehensive decrease in HSV-1 infection using a DNA aptamer. Their role in inhibiting cell to cell fusion and consecutively restrict viral spread was also evaluated in this study. Future studies will shed more light on the clinical implications of this aptamer.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×